Steady-State Pharmacokinetics of a New Antipsychotic Agent Perospirone and Its Active Metabolite, and Its Relationship with Prolactin Response

Authors:
  • HFHanako Furukori
    Hanako Furukori
  • TNTaku Nakagami
    Taku Nakagami
  • MSManabu Saito
    Manabu Saito
  • YIYoshimasa Inoue
    Yoshimasa Inoue
  • SKSunao Kaneko
    Sunao Kaneko
  • TTTomonori Tateishi
    Tomonori Tateishi

Abstract
The authors investigated steady-state pharmacokinetics of perospirone and its active metabolite hydroxyperospirone (ID-15036) and its prolactin response in 10 schizophrenic patients receiving 16 mg twice daily. Plasma concentrations of perospirone, hydroxyperospirone, and prolactin were monitored just before and up to 12 hours after the dosing. Thereafter, the dose was decreased to 8 mg twice daily in 8 patients, and drug concentrations were determined. The geometric means of peak concentration (Css max), time to C ss max(tmax), area under the plasma concentration-time curve from 0 to 12 hours [AUC (0–12)], and elimination half-life at steady state were 8.8 ng/mL, 0.8 hours, 22.0 ng·h/mL, and 1.9 hours, respectively, for perospirone, and those of Css max, tmax, and AUC (0–12) for hydroxyperospirone were 29.4 ng/mL, 1.1 hours, and 133.7 ng·h/mL, respectively. There were no differences in dose-normalized Css max or AUC (0–12) perospirone and hydroxyperospirone between 16 mg/day and 32 mg/day of perospirone. Changes in prolactin concentration from 1 to 2 hours after the dosing were parallel with drug concentrations, and almost normal ranges of prolactin concentration were observed before the morning dose despite steady state. The current study indicated that perospirone is rapidly absorbed and rapidly eliminated, which influences the prolactin response. The active metabolite hydroxyperospirone may play an important role in the antipsychotic effect because the plasma concentration of this metabolite is higher than that of the parent compound.
Keywords

This publication has 13 references indexed in Scilit: